Evidence map›Paper›PMID 37966661›Full record

ArticleMedical oncology (Northwood, London, England)2023

Examining the effect of activated cytotoxic (CD8

Eldar Sovunjov, Zehra Seda Halbutoğulları, Gülçin Gacar, Ahmet Öztürk, Gökhan Duruksu, Yusufhan Yazır

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Eldar SovunjovDepartment of Medical Biology, Faculty of Medicine, Kocaeli University, İzmit, Kocaeli, Turkey.
Zehra Seda HalbutoğullarıDepartment of Medical Biology, Faculty of Medicine, Kocaeli University, İzmit, Kocaeli, Turkey. sedahalbutogullari@kocaeli.edu.tr.ORCID http://orcid.org/0000-0001-6810-4939
Gülçin GacarDepartment of Stem Cell, Institute of Health Sciences, Kocaeli University, İzmit, Kocaeli, Turkey.
Ahmet ÖztürkDepartment of Stem Cell, Institute of Health Sciences, Kocaeli University, İzmit, Kocaeli, Turkey.
Gökhan DuruksuDepartment of Stem Cell, Institute of Health Sciences, Kocaeli University, İzmit, Kocaeli, Turkey.
Yusufhan YazırDepartment of Stem Cell, Institute of Health Sciences, Kocaeli University, İzmit, Kocaeli, Turkey.
Kocaeli Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer continues to be a major health problem worldwide owing to its incidence, and causes physical, psychological, social, and economic problems. Activated cytotoxic T cells (ACTC) are positively correlated with the tumor microenvironment (TME), improving the prognosis of cancer patients. Recently, ACTC-derived exosomes (ACTC-dExo) were implicated in this effect by inhibiting mesenchymal stem cells, which may promote metastasis in the TME. Exosomes are thought to be advantageous for the specific delivery of drugs to cancer cells because they have the characteristics of natural liposomes, are nanosized, and remain largely stable in the blood due to the protein and lipid content they carry on their membranes. In this study, we aimed to determine the cytotoxic and metastatic inhibitory effects of ACTC-dExo in A549 cells in vitro. Cytotoxic CD8

Indexed as

Antineoplastic AgentsExosomesLung NeoplasmsCD8-Positive T-LymphocytesHumansMatrix Metalloproteinase 2Matrix Metalloproteinase 9Tumor MicroenvironmentAntineoplastic AgentsMatrix Metalloproteinase 2Matrix Metalloproteinase 9Cytotoxic CD8+ T cellsExosomesImmunotherapyLung cancerMetastasis

Identifiers

PMID37966661
OpenAlexW4388699326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.